Brief: Genprex Says Co Poised for FDA Guidance On Diabetes Gene Therapy Program In 2024
05/01/2024 12:02
Jan 5 (Reuters) - Genprex Inc GNPX.O :
* GENPREX PROVIDES BUSINESS UPDATE AND OUTLOOK FOR 2024
* GENPREX INC: POISED FOR FDA GUIDANCE REGARDING DIABETES
GENE
THERAPY PROGRAM IN 2024
* GENPREX INC: ACCLAIM-1 PHASE 2A AND ACCLAIM-3 PHASE 1
CLINICAL
STUDIES OPENING FOR ENROLLMENT IN JANUARY 2024
Source text for Eikon: ID:nPn7nxGCZa
Further company coverage: GNPX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Genprex
See all newsBrief: Genprex Announces Collaboration With Roche Diagnostics For Biomarker Assay Validation Studies
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Genprex Announces Ip Australia's Intent To Grant Patent For Reqorsa® Gene Therapy